BNP Paribas Sells 194 Shares of Johnson & Johnson (NYSE:JNJ)

BNP Paribas lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 16,086 shares of the company’s stock after selling 194 shares during the quarter. BNP Paribas’ holdings in Johnson & Johnson were worth $2,606,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Johnson & Johnson by 51.0% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 296,000 shares of the company’s stock valued at $47,970,000 after acquiring an additional 100,000 shares during the period. Glenmede Trust Co. NA lifted its position in shares of Johnson & Johnson by 3.1% during the third quarter. Glenmede Trust Co. NA now owns 1,662,889 shares of the company’s stock worth $269,488,000 after purchasing an additional 49,891 shares during the last quarter. Hardy Reed LLC boosted its stake in shares of Johnson & Johnson by 1.1% during the third quarter. Hardy Reed LLC now owns 12,413 shares of the company’s stock valued at $2,012,000 after purchasing an additional 140 shares during the period. RBO & Co. LLC grew its holdings in shares of Johnson & Johnson by 0.8% in the third quarter. RBO & Co. LLC now owns 211,920 shares of the company’s stock worth $34,344,000 after purchasing an additional 1,782 shares during the last quarter. Finally, Townsquare Capital LLC lifted its holdings in Johnson & Johnson by 12.9% during the 3rd quarter. Townsquare Capital LLC now owns 123,812 shares of the company’s stock valued at $20,065,000 after buying an additional 14,185 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.8 %

NYSE JNJ opened at $154.51 on Wednesday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The company has a 50 day moving average price of $159.73 and a 200 day moving average price of $156.39. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market cap of $372.00 billion, a PE ratio of 22.36, a price-to-earnings-growth ratio of 2.77 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.66 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.21%. Johnson & Johnson’s payout ratio is 71.78%.

Analysts Set New Price Targets

JNJ has been the topic of a number of research analyst reports. Morgan Stanley upped their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Guggenheim raised their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Royal Bank of Canada upped their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $175.94.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.